Welcome to our dedicated page for Janux Therapeutics news (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics stock.
Janux Therapeutics reports developments for a clinical-stage biopharmaceutical business focused on tumor-activated immunotherapies and immune-engaging drug candidates. The company applies its TRACTr, TRACIr and ARM platforms to programs in oncology and autoimmune disease, including PSMA-directed prostate cancer candidates and a CD19-targeted ARM candidate.
Recurring news themes include clinical progress for JANX007, JANX014 and JANX011, portfolio decisions such as the discontinued JANX008 program, financial results and business highlights, collaboration milestones with Bristol Myers Squibb, and leadership or governance updates tied to the company’s clinical development organization.
Janux Therapeutics (Nasdaq: JANX) reported Q1 2026 results and pipeline updates on May 7, 2026. Key items: cash and short-term investments $956.4M, a $35M milestone from Bristol Myers Squibb after a development candidate nomination, initiation of clinical evaluation for JANX014, continued JANX007 Phase 1b enrollment including a darolutamide combination cohort, discontinuation of JANX008 after Phase 1a, and ongoing JANX011 Phase 1 dosing.
The company appointed William Go, M.D., Ph.D. as CMO and outlined clinical milestones through H1–H2 2026–2027.
Janux (Nasdaq: JANX) announced discontinuation of clinical development for JANX008, its EGFR-targeted TRACTr program, after completing Phase 1a dose-escalation and expansion cohorts on April 27, 2026. The company cited predefined development criteria: while durable responses occurred in select patients, overall activity magnitude and consistency were insufficient versus other programs.
Findings: cytokine release syndrome (CRS) was infrequent and mainly Grade 1 enabling outpatient dosing; tolerability was differentiated from conventional EGFR therapies; musculoskeletal adverse events were dose-limiting. Janux will prioritize other pipeline opportunities and retain the broader TRACTr platform strategy.
Janux Therapeutics (NASDAQ: JANX) announced the first patient has been dosed in a first-in-human Phase 1 study of JANX014 for metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a PSMA-directed, tumor-activated T cell engager exploring enhanced safety and administration versus existing approaches. The company cites favorable early JANX007 safety data and plans to advance JANX013 into the clinic in 2H2026.
The open-label trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in adults with mCRPC; trial details will be posted at clinicaltrials.gov.
Janux Therapeutics (Nasdaq: JANX) announced a development candidate nomination under its collaboration with Bristol Myers Squibb, triggering a $35 million milestone payment. The program uses Janux's TRACTr tumor-activated platform and targets an undisclosed solid tumor antigen.
Under the agreement Janux will complete preclinical work through IND submission and support the first Phase 1 study; Bristol Myers Squibb will hold the IND and lead subsequent clinical development and global commercialization. Janux remains eligible for additional milestones and tiered royalties on sales.
Janux Therapeutics (Nasdaq: JANX) reported Q4 and full-year 2025 results highlighting clinical progress, a strategic collaboration with Bristol Myers Squibb, leadership hiring, and a strong year-end balance sheet. Key metrics include $966.6M cash and investments, Phase 1 activity across JANX007/008/011, and a $50M near-term collaboration payment.
Clinical readouts show median rPFS of 7.9–8.9 months for JANX007 and confirmed/unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients. Company expects additional 2026 updates.
Janux Therapeutics (Nasdaq: JANX) announced dosing of the first participant in a Phase 1 study of JANX011, a CD19-targeted bispecific from its ARM platform designed for autoimmune diseases.
JANX011 produced deep, durable B-cell depletion and memory B-cell reset in preclinical single-dose studies across a >100-fold dose range with low cytokine levels; the open-label, dose-escalation trial (NCT07291323) will assess safety, PK, and PD in healthy adults to inform dose selection and indication prioritization.
Janux Therapeutics (NASDAQ:JANX) appointed William Go, M.D., Ph.D., as Chief Medical Officer effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., and brings more than 20 years of hematology and oncology experience, including leadership on the pivotal ZUMA-1 trial and development roles at A2 Biotherapeutics, Kite Pharma, and Amgen.
Janux is advancing multiple early-stage programs: JANX007 (PSMA TRACTr) and JANX008 (EGFR TRACTr) in Phase 1 trials across prostate and several solid tumor indications, plus additional TRACTr/TRACIr and an ARM CD19 program aimed at autoimmune diseases.
Janux Therapeutics (NASDAQ: JANX) on January 22, 2026 announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen.
Under the deal Janux will complete preclinical work through IND submission; Bristol Myers Squibb will hold the IND and lead subsequent development and global commercialization while Janux supports completion of the first Phase 1 study.
Financial terms include up to $50 million in upfront and near-term milestone payments, up to approximately $800 million in development, regulatory and commercial milestones, plus tiered royalties on global sales.
Janux Therapeutics (Nasdaq: JANX) provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr for multiple solid tumors.
The company said the Phase 1a dose-escalation portion (NCT05783622) is complete and expansion cohorts have been initiated to further evaluate safety, PK/PD and evidence of clinical activity across selected tumor types; Janux expects additional updates as data mature.
Janux also summarized its pipeline: JANX007 (PSMA-TRACTr) in Phase 1 for mCRPC, additional CD3-TRACTr and CD28-TRACIr programs (including PSMA-TRACIr and TROP2-TRACTr), and a CD19-ARM program advancing toward clinical evaluation.
Janux (NASDAQ: JANX) reported updated interim Phase 1 data for JANX007, a PSMA-directed TRACTr in mCRPC, with data cut-off Oct 15, 2025. Across Phase 1a/b, 109 patients were treated; Phase 1a patients had a median of 4 prior lines of therapy while Phase 1b enrolled taxane-naïve patients.
Key efficacy signals include confirmed/unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients and rPFS of 7.9–8.9 months. Taxane-naïve expansion showed rapid, deep PSA reductions. Safety was described as manageable with CRS primarily grade 1–2 limited to cycle 1 and an identified CRS mitigation strategy. Janux plans monotherapy and darolutamide combinations and will evaluate PARP inhibitor–refractory patients.